Table 2.

Mean IC₅₀ values (μM) of the tested compounds over in vitro subpanel cancer cell lines^a.

Subpanel cancer lineb
	I	II	III	IV	V	VI	VII	VIII	IX
No. of cell lines in each subpanel	5	8	7	6	9	7	8	2	6
1h	2.25	3.12	2.35	2.48	1.44	2.81	2.97	2.11	2.25
1i	1.15	1.67	1.00	1.29	0.94	2.41	1.67	0.99	2.32
1j	0.41	0.85	0.54	0.55	0.71	1.16	0.80	0.44	0.74
1l	0.72	1.48	0.68	1.58	1.03	2.02	1.51	1.13	2.06
Sorafenib	2.43	2.25	2.19	2.33	1.87	2.88	2.94	2.58	2.17

^aMean IC₅₀ values were calculated by dividing the summation of IC₅₀ values of the compound over cell lines of the same cancer type by the number of cell lines in the subpanel. ^bI: Leukemia; II: non-small cell lung cancer; III: colon cancer; IV: CNS Cancer; V: melanoma VII: ovarian cancer; VII: renal cancer; VIII: prostate cancer; IX: breast cancer. Bold figures indicate superior potency than the reference drug, Sorafenib.